Neoadjuvant botensilimab (BOT) plus balstilimab (BAL) in resectable mismatch repair proficient (pMMR) and deficient (dMMR) colorectal cancer (CRC): NEST clinical trial update.

Authors: Erika Hissong, Mehraneh D. Jafari, Sahrish Khan, Pashtoon Murtaza Kasi, Preethi Guniganti, Allyson J. Ocean, Despina Siolas, Heather Yeo, Uqba Khan, Alessio Pigazzi, Areeb Lutfi, Zhengming Chen, Manish A. Shah, Manuel Hidalgo

Published: 2025-01-27

DOI: 10.1200/jco.2025.43.4_suppl.207

Source: Full article

---

Abstract

207